KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Current Deferred Revenue (2017 - 2025)

Aquestive Therapeutics (AQST) has 8 years of Current Deferred Revenue data on record, last reported at $1.1 million in Q4 2025.

  • For Q4 2025, Current Deferred Revenue rose 4.2% year-over-year to $1.1 million; the TTM value through Dec 2025 reached $1.1 million, up 4.2%, while the annual FY2025 figure was $1.1 million, 4.2% up from the prior year.
  • Current Deferred Revenue reached $1.1 million in Q4 2025 per AQST's latest filing, roughly flat from $1.1 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $37.8 million in Q1 2023 and bottomed at $437000.0 in Q1 2021.
  • Average Current Deferred Revenue over 5 years is $8.5 million, with a median of $1.3 million recorded in 2022.
  • Peak YoY movement for Current Deferred Revenue: skyrocketed 3444.39% in 2022, then tumbled 97.18% in 2024.
  • A 5-year view of Current Deferred Revenue shows it stood at $765000.0 in 2021, then skyrocketed by 97.78% to $1.5 million in 2022, then grew by 2.51% to $1.6 million in 2023, then plummeted by 32.43% to $1.0 million in 2024, then grew by 4.2% to $1.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Deferred Revenue were $1.1 million in Q4 2025, $1.1 million in Q3 2025, and $21.0 million in Q2 2025.